Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 301 - 325 of 8028 in total
Mifamurtide is an immunomodulator with antitumor activity via activation of macrophages and monocytes. Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP). MDP is a motif present in all gram-positive and...
Approved
Experimental
Matched Description: … Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is ... The overall result of MDP recognition leads to the production of proinflammatory cytokines and promotion ... of bactericidal and tumoricidal effects [A31745]. …
Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout...
Approved
Matched Description: … [L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around ... Febuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric ... [A230548] In the following year, the FDA for approved febuxostat for use in the chronic management of
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole...
Approved
Investigational
Matched Description: … The side effect profile of this drug is minimal. ... and superficial fungal infections in a variety of tissues. ... Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic …
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of
Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments, tendons) are replaced...
Approved
Investigational
Matched Description: … ], which are derivatives of [vitamin A]. ... Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million ... [A244920] FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive …
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into...
Approved
Investigational
Matched Description: … is the subject of many clinical trials in a variety of cancer types. ... of anticonvulsive activity. ... It is currently a compound of interest in the field of oncology for its anti-proliferative effects and …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Pepsin is a potent enzyme in gastric juice that digests proteins such as those in meat, eggs, seeds, and dairy products . Studies on gastric digestion from 1820-1840 led to the discovery of pepsin as the substance which, in the presence of stomach acid, causes nutrients including meat or coagulated...
Approved
Experimental
Investigational
Matched Description: … Stimulation of the pancreas and therefore enzymatic digestion of food is a tightly controlled and is ... Studies on gastric digestion from 1820-1840 led to the discovery of pepsin as the substance which, in ... the presence of stomach acid, causes nutrients including meat or coagulated egg whites to dissolve. …
Peanut oil is derived from Arachis hypogaea which can be found in South America, Mexico, and Centro America. The kernels are consumed roasted but a large percentage is used for the production of vegetable oil. The peanut oil represents about 45-52% of the kernel content and it is mainly formed...
Approved
Matched Description: … The kernels are consumed roasted but a large percentage is used for the production of vegetable oil. ... The peanut oil represents about 45-52% of the kernel content and it is mainly formed from monounsaturated …
Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule. It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA). AMD is the leading cause of vision loss in developed countries for people over 50 years old, with...
Approved
Investigational
Matched Description: … with a global estimate of 170 million individuals affected. ... the non-neovascular (dry) or the neovascular (wet) form of AMD. ... It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic …
Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs...
Approved
Matched Description: … [A188514] It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, ... , each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater …
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone...
Approved
Matched Description: … Nisoldipine may be used in alone or in combination with other agents in the management of hypertension ... By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth …
Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was...
Approved
Matched Description: … Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl ... This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the …
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been...
Approved
Matched Description: … life of patients and caregivers. ... treat manic episodes in bipolar disorder although the mechanism of action is unknown. ... several treatment options for psychotic disorders have been introduced to market since the realization of
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also...
Approved
Investigational
Matched Categories: … Sex Hormones and Modulators of the Genital System …
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the...
Approved
Investigational
Matched Description: … triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of ... [T646] A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms ... reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906.[A229008,A228593,A229108] Like all other neurohypophysial hormones, oxytocin is composed of nine amino acids with a disulfide bridge between the Cys 1 and 6 residues.[A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent...
Approved
Vet approved
Matched Description: … [A229008,A228593,A229108] Like all other neurohypophysial hormones, oxytocin is composed of nine amino ... [A229108,A229113] It is estimated that labor induction with oxytocin is used in almost 10% of deliveries …
A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Approved
Vet approved
Matched Description: … A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. …
Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and trichinellosis . Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use...
Approved
Vet approved
Matched Description: … Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm ... Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of ... Pyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and …
Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.[A254167,A254162] Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces...
Approved
Investigational
Matched Description: … for non-dialysis patients with anemia of CKD. ... As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular ... [A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. …
Approved
Experimental
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage...
Approved
Investigational
Matched Description: … [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated ... [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients ... (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Matched Description: … Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. ... [L32803] In clinical trials, vildagliptin has a relatively low risk of hypoglycemia. ... [A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP- …
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. ... subsequently approved by the European Commission in April 2022 for both the treatment and prevention of ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine …
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in...
Approved
Matched Description: … Degarelix is used for the treatment of advanced prostate cancer. ... Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which …
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … baricitinib for the treatment of COVID-19 in May 2022. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of
Displaying drugs 301 - 325 of 8028 in total